(Q42947493)

English

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

scientific article published on November 1, 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV (English)

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

bioavailability

1 reference

based on heuristic

inferred from title

author name string

Polina German

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

David Warren

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Steve West

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

James Hui

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Brian P. Kearney

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20683270

16 June 2024

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Journal of Acquired Immune Deficiency Syndromes

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

323-329

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

1

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

2

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients

3

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

4

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives

5

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137

6

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Mechanism of active renal tubular efflux of tenofovir

7

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

8

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

9

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

11

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

12

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir

13

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance

14

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.

15

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily

16

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

17

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor

18

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial

19

1 reference

10.1097/QAI.0B013E3181EB376B

https://api.crossref.org/works/10.1097/QAI.0B013E3181EB376B

16 June 2024

Identifiers

10.1097/QAI.0B013E3181EB376B

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42947493&oldid=2181163510"